Live Feeds
● LIVE Updated 1h ago · 13 sources tracked

People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study

Adults with overweight or obesity who transitioned from injectable GLP-1 weight-loss medications to Novo Nordisk's once-daily oral semaglutide pill continued to drop pounds in a real-world study. Patients who remained on the Wegovy pill for three months achieved an average weight loss of 4.1%, equivalent to 8.8 pounds from an average starting weight of 221.6 pounds. The data indicates patients may not require weekly injections indefinitely and can transition to more convenient oral therapies without halting their progress.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Patients with overweight or obesity who switched from injectable GLP-1 therapies to the once-daily oral semaglutide Wegovy pill and stayed on treatment for three months lost an average of 4.1% or 8.8 pounds.
  • ✓ The analysis was based on an average starting weight of 221.6 pounds among participants in the OCTANE study.
  • ✓ The OCTANE study analyzed de-identified data drawn from the Ro telehealth platform.
🛡️ Source Corroboration: 13 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novo Nordisk released new real-world data from the OCTANE study at EASD2026 showing that patients switching from injections to the oral Wegovy pill lost an average of 4.1% of their body weight after three months.

Live updates

  1. Wegovy Pill Maintained Weight Loss After Injection Switch

    Adults with overweight or obesity who transitioned from injectable GLP-1 weight-loss medications to Novo Nordisk's once-daily oral semaglutide pill continued to drop pounds in a real-world study. Patients who remained on the Wegovy pill for three months achieved an average weight loss of 4.1%, equivalent to 8.8 pounds from an average starting weight of 221.6 pounds. The data indicates patients may not require weekly injections indefinitely and can transition to more convenient oral therapies without halting their progress.

    Why it matters

    The findings stem from the OCTANE study, which analyzed de-identified data from the Ro telehealth platform and was presented at EASD2026. The research collaboration between Ro and Novo Nordisk seeks to generate real-world evidence for the oral treatment option. Medical professionals observe that this flexibility addresses long-term management preferences for individuals using GLP-1 medications.

    What is confirmed

    • Patients with overweight or obesity who switched from injectable GLP-1 therapies to the once-daily oral semaglutide Wegovy pill and stayed on treatment for three months lost an average of 4.1% or 8.8 pounds.
    • The analysis was based on an average starting weight of 221.6 pounds among participants in the OCTANE study.
    • The OCTANE study analyzed de-identified data drawn from the Ro telehealth platform.

    What to watch next

    • Further clinical data on long-term adherence and weight maintenance beyond the initial three-month window.
    • Additional real-world evidence initiatives arising from the Ro and Novo Nordisk research collaboration.
    Sources used for this update (14)
    1. Reuters — Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
    2. CNBC — People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
    3. qz.com — Switching to Novo Nordisk's weight loss pill helped people keep shedding pounds
    4. PR Newswire — Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill
    5. marketscreener.com — Oral Wegovy option confirms its effectiveness in real-world data
    6. finance.yahoo.com — Novo Nordisk Wegovy pill weight loss switch study results
    7. Pharmaceutical Executive — Peptide Ruling Stalls | PharmExec
    8. FirstWord Pharma — EASD26: Novo says people switching from injectable GLP-1s to oral Wegovy continue losing weight
    9. STAT — Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
    10. www.cnbc.com — Novo's Wegovy pill improves weight loss after switch from ...
    11. www.prnewswire.com — People switching from weight-loss injections to Novo's Wegovy ...
    12. www.biospace.com — People switching from weight-loss injections to Novo's Wegovy ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community